Treatment

innohep® 10.000 anti Xa IU/0,5mL PF.SYR. Ενέσιμο διάλυμα, innohep® 18.000 anti Xa IU/0,9mL PF.SYR. Ενέσιμο διάλυμα, innohep® 14.000 anti Xa IU/0,7mL PF.SYR. Ενέσιμο διάλυμα clinical trials

1 indexed studies · 0 currently recruiting

AuthorisedTherapeutic confirmatory (Phase III)
The impact of Thromboprophylaxis on Progression Free Survival of Patients with Advanced Pancreatic Cancer. The Pancreatic Cancer & Tinzaparin Prospective (imPaCT-PRO) study
This study looks at whether a blood-thinning medicine called innohep® can help people with advanced pancreatic cancer live longer without their cancer getting worse. It also checks if it helps prevent blood clots. It's a key stage 3 trial.
For: Thromboprophylaxis in patients with advanced pancreatic cancer
Greece